Patients must have signed an approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
164.0
Ability to give informed consent
348.0
All patients or their legal guardians (if the patient is < 18 years old) or durable power of attorney (DPA) must sign a document of informed consent indicating their understanding of the investigational nature and the risks of this study; when appropriate, pediatric patients will be included in all discussions in order to obtain verbal assent
30.0
Signed informed consent according to institutional guidelines must be obtained
30.0
Able and willing to sign informed consent/assent
143.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; for Step 1 registration of patients who have not yet submitted specimens for the Oncotype DX Breast Cancer Assay, the appropriate consent form is the Step 1 Consent Form; for both Step 1 and Step 2 registration of patients whose Recurrence Score is already known and is 25 or less, the appropriate consent form is the Step 2 Consent Form
10000.0
PROCUREMENT: Patient able to give informed consent
44.0
TREATMENT: Patient able to give informed consent
44.0
A medical or psychiatric illness that precludes ability to give informed consent or is likely to interfere with the ability to comply with the protocol stipulations
90.0
Patients must consent to be in the study and must have signed and dated an approved consent form, which conforms to federal and institutional guidelines
45.0
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
1636.0
Signed informed consent by subject (age >= 18 years) or by parent/guardian (subject age < 18 years); information will be provided to potential subjects and their parents/guardians (as appropriate) by oral discussion with opportunity for question and answer and the written informed consent document; subjects less than 18 years of age capable of giving assent will be included in these discussions and will be asked for written assent on the same document as the parents/guardians give consent; if feasible, both parents (or guardians) will be included in these discussions and will be asked to sign the written consent document; if a second parent or guardian is unavailable, this will be explained in writing on the written consent document; if subjects age 18 years or older are unable to provide informed consent, then they will not be enrolled in this study
75.0
Willingness to sign the healthy volunteer informed consent form
140.0
Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves
80.0
Patients who do not consent for PK studies to be performed (alternatively: patients who initially consent to be on study but withdraws consent for PK study will be taken off study and replaced)
30.0
Diagnostic or laboratory studies performed exclusively to determine eligibility for this trial must only be done after obtaining written informed consent from all patients or their legal guardians (if the patient is < 18 years old); when appropriate, pediatric patients will be included in all discussions; this can be accomplished through one of the following mechanisms: a) the NCI, POB screening protocol, b) an Institutional Review Board (IRB)-approved institutional screening protocol or c) the study-specific protocol; documentation of the informed consent for screening will be maintained in the patient�s research chart; studies or procedures that were performed for clinical indications (not exclusively to determine eligibility) may be used for baseline values even if the studies were done before informed consent was obtained
104.0
Cognitive impairment, history of medical or psychiatric disease, other uncontrolled intercurrent illness, active substance abuse, or social circumstances, which in the view of the principal investigator (PI), would preclude safe treatment or the ability to give informed consent
52.0
Able to provide informed consent, or if the oncology physician determines the patient to not have decision-making capacity, a patient-designated health care proxy (or authorized representative per institutional policies) must sign consent by the baseline visit; if the participant is found to be impaired on the Blessed-Orientation Memory Concentration Test (BOMC) during screening; they must have a health care proxy or authorized representative to be eligible to enroll
700.0
All patients and/or their parent or legal guardian must sign a written informed consent
598.0
Patients must NOT suffer from medical or psychiatric conditions that would interfere with protocol compliance, the ability to provide informed consent, or assessment of response or anticipated toxicities; this includes uncontrolled intercurrent illness including, but not limited to ongoing or active infection
600.0
Ability to provide informed consent; all subjects must sign an informed consent form indicating their understanding of the investigational nature and risks of the study before any protocol-related studies are performed
125.0
Patient or appointed surrogate decision-maker or legally authorized representative must have ability to understand the purpose and risks of the study and willingness to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations)
52.0
Inability to understand and inability to provide informed consent
42.0
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
990.0
The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document, inclusive of assent where appropriate, according to institutional guidelines
110.0
INCLUSION CRITERIA FOR STRATUM C: The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document, inclusive of assent where appropriate, according to institutional guidelines
110.0
Diagnostic or laboratory studies performed exclusively to determine eligibility for this trial must only be done after obtaining written informed consent from all patients, which can be accomplished using the NCI, POB screening protocol; studies or procedures that were performed for clinical indications (not exclusively to determine eligibility) may be used for screening or baseline values even if the studies were done before informed consent was obtained, if the patient agrees
50.0
Signed, written informed consent
23.0
Other uncontrolled, concurrent illness that would preclude study participation; or, psychiatric illness or social challenges that would entail unreasonable risk or preclude informed consent or compliance with study procedures
23.0
Inability to understand and sign informed consent
33.0
Written informed consent (IC) for trial participation must be signed and dated by the patient and the investigator prior to enrollment
500.0
Written consent to biological material submission, indicating the patient has been informed of and agrees to tissue and blood material use, transfer and handling, must be signed and dated by the patient and the investigator prior to any procedures specific for this trial
500.0
Any perceived inability to directly (and without the means of a legal guardian) provide informed consent
18.0
Medical or psychiatric illness or social situations that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves
60.0
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines
50.0
NON-PROGRESSED DIPG (STRATUM 2): The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines
50.0
Patients must be able to understand and sign an informed consent form
24.0
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
348.0
Signed, dated informed consent
766.0
The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines
25.0
Diagnostic or laboratory studies performed exclusively to determine eligibility for this trial must only be done after obtaining written informed consent from all patients, which can be accomplished using the study specific informed consent or another consent, such as the National Cancer Institute (NCI), Pediatric Oncology Branch (POB) screening protocol; studies or procedures that were performed for clinical indications (not exclusively to determine eligibility) may be used for screening or baseline values even if the studies were done before informed consent was obtained, if the patient agrees
24.0
Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
40.0
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
175.0
Patients must have signed informed consent indicating that they are aware of the investigational nature of the study, and are aware that participation is voluntary; patients must be made aware of their other treatment options
21.0
Have been informed of other treatment options
78.0
Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
78.0
Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
78.0
All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
162.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; for all patients the appropriate consent form for this registration is the Step 2 Consent
10000.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
155.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
1900.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
130.0
All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
491.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
97.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
38.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
10000.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
10000.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent prior to any study-related procedures in accordance with institutional and federal guidelines
230.0
ALL PATIENTS: Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
44.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
280.0
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
200.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
223.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
150.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
180.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
333.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
143.0
REGULATORY CRITERIA: Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
53.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
3960.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
77.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
148.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines
1000.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
64.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
150.0
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
94.0
All patients and/or their parents or legal guardians must sign a written informed consent
400.0
All patients and/or their parents or legal guardians must sign a written informed consent
253.0
All patients and/or their parents or legal guardians must sign a written informed consent
500.0
All patients and/or their parents or legal guardians must sign a written informed consent
9483.0
All patients and/or their parents or legal guardians must sign a written informed consent
693.0
All patients and/or their parents or legal guardians must sign a written informed consent
608.0
All patients and/or their parents or legal guardians must sign a written informed consent (patient assent is also recommended when applicable according to each institution�s policy)
71.0
All patients and/or their parents or legal guardians must sign a written informed consent
275.0
All patients and/or their parents or legal guardians must sign a written informed consent
450.0
All patients and/or their parents or legal guardians must sign a written informed consent
621.0
All patients and/or their parents or legal guardians must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
1400.0
All patients and/or their parents or legal guardians must sign a written informed consent
600.0
All patients and/or their parents or legal guardians must sign a written informed consent
340.0
All patients and/or their parents or legal guardians must sign a written informed consent
158.0
All patients and/or their parents or legal guardians must sign a written informed consent
330.0
Each patient�s parents or legal guardians must sign a written informed consent
256.0
All patients and/or their parents or legal guardians must sign a written informed consent
90.0
All patients and/or their parents or legal guardians must sign a written informed consent.
337.0
All patients and/or their parents or legal guardians must sign a written informed consent
56.0
All patients and/or their parents or legal guardians must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
45.0
All patients and/or their parents or legal guardians must sign a written informed consent
250.0
All patients and/or their parents or legal guardians must sign a written informed consent
90.0
All patients and/or their parents or legal guardians must sign a written informed consent
700.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
77.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
154.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
148.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
484.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
81.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
67.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
65.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
36.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
51.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
49.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
98.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
49.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
49.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
144.0
All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
49.0
Patients must have signed an approved informed consent and authorization permitting release of personal health information
1070.0
Patients must have signed an approved informed consent and authorization permitting release of personal health information
128.0
Patients must have signed an approved informed consent and authorization permitting release of personal health information
360.0
Patients must have signed an approved informed consent and authorization permitting release of personal health information
NONE
Patients must have signed an approved informed consent and authorization permitting release of personal health information
52.0
Patients must have signed an approved informed consent and authorization permitting release of personal health information
600.0
Patients must have signed an approved informed consent and authorization permitting release of personal health information; individuals with impaired decision-making capacity are not eligible to participate on the study
540.0
Patients must have the ability to understand and sign an approved informed consent and authorization permitting release of personal health information
250.0
Patients must have signed an approved informed consent and authorization permitting release of personal health information
549.0
The patient must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
84.0
The patient or legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
488.0
The patient or a legally authorized representative must provide study-specific informed consent and authorization permitting release of personal health information prior to study entry
50.0
Ability to understand and the willingness to sign a written informed consent document
36.0
Ability to understand and the willingness to sign a written informed consent document
276.0
Ability to understand and the willingness to sign a written informed consent document
74.0
Ability to understand and the willingness to sign a written informed consent document; subjects must be willing to adhere to dose and visit schedules
130.0
Ability to understand and the willingness to sign a written informed consent document
40.0
Ability to understand and the willingness to sign a written informed consent document
107.0
Ability to understand and the willingness to sign a written informed consent document
132.0
Ability to understand and the willingness to provide written informed consent to participate
90.0
Ability to understand and the willingness to sign a written informed consent document
24.0
Ability to understand and the willingness to sign a written informed consent document
110.0
Ability to understand and the willingness to sign a written informed consent document
55.0
Ability to understand and the willingness to sign a written informed consent document according to institutional guidelines
180.0
Ability to understand and the willingness to sign a written informed consent document
70.0
Ability to understand and the willingness to sign a written informed consent document
165.0
Ability to understand and the willingness to sign a written informed consent document
113.0
Ability to understand and the willingness to sign a written informed consent document
42.0
Ability to understand and the willingness to sign a written informed consent document and to undergo tumor biopsies in the expansion phase
140.0
Ability to understand and the willingness to sign a written informed consent document
72.0
Ability to understand and the willingness to sign a written informed consent document
80.0
Ability to understand and the willingness to sign a written informed consent document
68.0
Ability to understand and the willingness to sign a written informed consent document
42.0
Ability to understand and the willingness to sign a written informed consent document
30.0
Ability to understand and the willingness to sign a written informed consent document
73.0
Ability to understand and the willingness to sign a written informed consent document
80.0
Ability to understand and the willingness to sign a written informed consent document
72.0
Ability to understand and the willingness to sign a written informed consent document
70.0
Ability to understand and the willingness to sign a written informed consent document
72.0
TUMOR BIOPSY SEQUENCING: Ability to understand and the willingness to sign a written informed consent document (subjects with impaired decision-making capacity are not eligible)
700.0
Ability to understand and the willingness to sign a written informed consent document
52.0
Ability to understand and the willingness to sign a written informed consent document
40.0
Ability to understand and the willingness to sign a written informed consent document
18.0
Ability to understand and the willingness to sign a written informed consent document
12.0
Ability to understand and the willingness to sign a written informed consent document
92.0
Ability to understand and the willingness to sign a written informed consent document; consent will be obtained by day 14 of AcDVP-16 induction regimen
63.0
Ability of patient to understand and the willingness to sign a written informed consent document
54.0
Ability to understand and the willingness to sign a written informed consent document
68.0
Ability to understand and the willingness to sign a written informed consent document
130.0
Ability to understand and the willingness to sign a written informed consent document
32.0
Ability to understand and the willingness to sign a written informed consent document
100.0
Patient and/or guardian have the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines
40.0
Ability to understand and the willingness to sign a written informed consent document
28.0
Ability to understand and the willingness to sign a written informed consent document
44.0
Ability to understand and the willingness to sign a written informed consent document
35.0
Ability to understand and the willingness to sign a written informed consent document
57.0
Ability to understand and the willingness to sign a written informed consent document
23.0
Ability to understand and the willingness to sign a written informed consent document
90.0
Ability to understand and the willingness to sign a written informed consent document
36.0
Participants must be able to understand and willing to sign a written informed consent document
56.0
Ability to understand and the willingness to sign a written informed consent document
80.0
Ability to understand and the willingness to sign a written informed consent document
18.0
Ability to understand and the willingness to sign a written informed consent document
135.0
Ability to understand and the willingness to sign a written informed consent document
37.0
Ability to understand and the willingness to sign a written informed consent document
66.0
Ability to understand written and/or spoken English
222.0
Ability to understand and willingness to sign a written informed consent document
222.0
Ability to understand and the willingness to sign a written informed consent document
209.0
Ability to understand and the willingness to sign a written informed consent document
58.0
Ability to understand and the willingness to sign a written informed consent document
35.0
Ability to understand and the willingness to sign a written informed consent document
30.0
Ability to understand and the willingness to sign a written informed consent document
30.0
Ability to understand and to sign a written informed consent document
84.0
Ability to understand and the willingness to sign a written informed consent document
30.0
Ability to understand and the willingness to sign a written informed consent document
46.0
Ability to understand and the willingness to sign a written informed consent document
45.0
Ability to understand and the willingness to sign a written informed consent document
33.0
Ability to understand and the willingness to sign a written informed consent document
35.0
Ability to understand and the willingness to sign a written informed consent document
82.0
Ability to understand and the willingness to sign a written informed consent document
126.0
Ability to understand and the willingness to sign a written informed consent document
37.0
Ability to understand and the willingness to sign a written informed consent document
36.0
Ability to understand and the willingness to sign a written informed consent document
50.0
Ability to understand and the willingness to sign a written informed consent document
46.0
Ability to understand and the willingness to sign a written informed consent document
15.0
Ability to understand and the willingness to sign a written informed consent document
46.0
Ability to understand and the willingness to sign a written informed consent document
36.0
Ability to understand and the willingness to sign a written informed consent document
90.0
Ability to understand and the willingness to sign a written informed consent document
45.0
Ability to understand and the willingness to sign a written informed consent document
50.0
Ability to understand and the willingness to sign a written informed consent document
32.0
Ability to understand and the willingness to sign a written informed consent document
18.0
Ability to understand and the willingness to sign a written informed consent document
46.0
Ability to understand and willingness to sign a written informed consent document
60.0
Able to understand and willingness to sign a written informed consent document
64.0
Ability to understand and the willingness to sign a written informed consent document
70.0
Ability to understand and the willingness to sign a written informed consent document
29.0
Ability to understand and willingness to sign a written informed consent document
51.0
Ability to understand and the willingness to sign a written informed consent document
150.0
Ability to understand and the willingness to sign a written informed consent document
48.0
Ability to understand and the willingness to sign a written informed consent document
20.0
Ability to understand and the willingness to sign a written informed consent document
36.0
Ability to understand and the willingness to sign a written informed consent document
60.0
Ability to understand and the willingness to sign a written informed consent document
38.0
Ability of subject or legally guardians (if the patient is < 18 years old) to understand and the willingness to sign a written informed consent document
70.0
Ability to understand and the willingness to sign a written informed consent document or a parent/guardian able to do the same
35.0
Ability to understand and the willingness to sign a written informed consent document
28.0
Ability to understand and the willingness to sign a written informed consent document
72.0
Ability to understand and the willingness to sign a written informed consent document
40.0
Ability to understand and the willingness to sign a written informed consent document
30.0
Ability to understand and the willingness to sign an Institutional Review Board (IRB) approved written informed consent document
60.0
Ability to understand and the willingness to sign a written informed consent document
48.0
Ability to understand and the willingness to sign a written informed consent document
90.0
Ability to understand and the willingness to sign a written informed consent document
132.0
Ability to understand and the willingness to sign a written informed consent document
40.0
Ability to understand and the willingness to sign a written informed consent document
22.0
Ability to understand and the willingness to sign a written informed consent document
40.0
Ability to understand and the willingness to sign a written informed consent document
27.0
Ability to understand and the willingness to sign a written informed consent document
98.0
Ability to understand and the willingness to sign a written informed consent document
70.0
Ability to understand and the willingness to sign a written informed consent document
68.0
Ability to understand and the willingness to sign a written informed consent document
21.0
Ability to understand and the willingness to sign a written informed consent document
47.0
Ability to provide informed consent
102.0
Written informed consent
360.0
Participant willing to provide a written informed consent
292.0
Able to give informed consent
240.0
Provide informed written consent
48.0
Provide informed written consent
1120.0
Ability to provide written informed consent
265.0
Willing to provide informed written consent
224.0
Inability to provide informed consent
90.0
Provide informed written consent
330.0
Ability to provide informed written consent
102.0
Patients must be able to provide written informed consent
36.0
Unable to provide informed consent
278.0
Patient must have given written informed consent
509.0
Ability to understand and willing to provide informed consent
150.0
Participant is unable to provide informed consent
5058.0
Patients must be able to provide written informed consent
40.0
Patients must be able to provide written informed consent
23.0
Inability to provide informed consent
18.0
Patients must be able to provide written informed consent
75.0
Capable and willing to provide informed consent
99.0
Be able to provide written informed consent
720.0
Written informed consent
400.0
Patients must be able to provide written informed consent
30.0
Patients must be able to provide written informed consent
35.0
Patients must be willing and able to provide a written informed consent
164946.0
Ability to understand and the willingness to sign a written informed consent document; if a patient has impaired decision-making capacity, a legally authorized representative, patients will be allowed to participate
68.0
Ability of subject or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document
50.0
Ability of subject or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document
24.0
Ability of subject or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document
24.0
Ability of a patient or a Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document
180.0
Patients must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for EGFR and for oropharyngeal patients, HPV analyses
700.0
Patients must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for central review
252.0
Patient must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for epidermal growth factor receptor (EGFR) analysis and for oropharyngeal cancer patients, human papilloma virus (HPV) analysis
660.0
Patient must provide study specific informed consent prior to study entry, including consent for mandatory screening of tissue
234.0
Patient must provide study specific informed consent prior to study entry, including the mandatory pre-treatment plasma EBV DNA assay
924.0
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry, including consent for mandatory tumor tissue, serum, and blood submission for immune correlatives (all patients) and p16 analysis (oropharyngeal cases only)
56.0
Signed study-specific informed consent
545.0
Signed study-specific informed consent prior to registration
317.0
Provision of informed consent prior to any study specific procedures
1500.0
Patients must provide study-specific informed consent prior to step 1 registration
606.0
Patients must provide study-specific informed consent prior to registration
510.0
The patient or a legally authorized representative must provide study-specific informed consent prior to step 1 registration
612.0
The patient or a legally authorized representative must provide study-specific informed consent prior to step 1 registration
282.0
The patient or a legally authorized representative must provide study-specific informed consent prior to study registration
186.0
Patient must provide study-specific informed consent prior to study entry
285.0
Patient must be able to provide study-specific informed consent prior to study entry
37.0
Patient must be able to provide study specific informed consent prior to study entry
2580.0
Patient must provide study specific informed consent prior to study entry
143.0
Patient must be able to provide study-specific informed consent prior to study entry
368.0
The ability to provide written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time
45.0
Patient must provide study-specific informed consent prior to study entry
330.0
Patient must provide study specific informed consent prior to study entry
84.0
Patient must provide study specific informed consent prior to study entry
182.0
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
360.0
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
96.0
Patient must have provided study specific informed consent prior to study entry
680.0
Patient must provide study specific informed consent prior to study entry
188.0
Patients must sign a study-specific informed consent prior to study entry
302.0
The patient must provide study-specific informed consent prior to study entry
147.0
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.
186.0
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
148.0
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
120.0
